BIOCYTOGEN-B (02315) saw its shares climb more than 13% during Wednesday's trading session, with the stock last up 11.61% at HK$63.95, and turnover reaching HK$103 million at the time of writing.

On the news front, the company's dual-engine strategy, which combines its "fully human antibody library" with its "target-humanized mouse library," has driven substantial gains in both revenue and profitability. Notably, the firm has now remained profitable for five consecutive quarters.

For the first half of this year, BIOCYTOGEN-B reported revenue of RMB 940 million, representing a 51.6% year-on-year increase, while net profit attributable to shareholders surged 402% to RMB 240 million. During the reporting period, total revenue from the preclinical segment climbed 57.9% year-on-year to RMB 723 million, with sales of innovative animal models reaching RMB 446 million, up 62.4% from the prior year, supported by a gross margin of 82.3%. Antibody development services generated RMB 218 million in revenue, marking a 33.8% increase while maintaining a robust gross margin of 92.8%.

The company signed over 105 new collaboration agreements during the period, bringing its cumulative total to 455 drug development, licensing, and transfer deals. More than 150 new agreements were inked, involving partnerships with over 150 pharmaceutical companies, with total disclosed transaction value amounting to tens of billions of RMB. Additionally, leveraging its million-scale repository of authentic fully human antibody sequences, the company has launched the RenSuper Workstation, signaling a shift in antibody drug development from the traditionally lengthy "concept-to-candidate-to-validation" process to a new era of intelligent, one-step drug creation.